Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma (HCC) who are listed for transplantationFull details appear in

read more>>

COLUMBUS, Ohio -- Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) have discovered how a substance that is produced when eating broccoli and Brussels sprouts can block the proliferation of C

read more>>

ABBOTT PARK, Ill. -- Abbott (NYSE: ABT) scientists and independent researchers will highlight the latest clinical trial data on four of Abbott's investigational oncology compounds at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 4-8 in ChicagoThe prese

read more>>

Every cell contains machinery for self-destruction, used to induce death when damaged or sickBut according to a new research study, a receptor thought to mediate cell suicide in normal cells may actually be responsible for the unrestrained growth of cancerous tumorsBlocking the activity of this "

read more>>

Hepatocellular carcinoma (HCC) responds poorly to chemotherapy owing to MDRRecent studies have shown the tumors derived from the colon, kidney, or adrenal cortex, and HCC exhibited overexpression of MDR1/P-gp. This overexpression results in a primary MDR phenotype of these cancers. Tumor derived c

read more>>

Hepatocellular carcinoma (HCC) is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulative functionSurgical resection is the best option to cure HCC, however, surgery on cirrhotic liver may increase the risk of bleeding. Desp

read more>>

Hepatocellular carcinoma (HCC) is an aggressive tumor with poor long-term prognosisThe reported 5-year recurrence rate ranges from 75% to 100%. Therefore, extrahepatic metastasis of HCC is uncommon due to the highly malignant nature of the primary tumor. However, with advances in different treatme

read more>>

San Diego -- NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer

read more>>

San Diego, CA -- NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its The

read more>>

The humble papaya is gaining credibility in Western medicine for anticancer powers that folk cultures have recognized for generationsUniversity of Florida researcher Nam Dang, M.D., Ph.D., and colleagues in Japan have documented papaya's dramatic anticancer effect against a broad range of lab-grow

read more>>